Molnár, P., Demény, M. Á., Várkonyi, B., Polgár, Z., Pór, Á., Kovács, I., . . . Szántó, M. (2025). The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation. Frontiers in pharmacology, 16, 1519066. https://doi.org/10.3389/fphar.2025.1519066
Citace podle Chicago (17th ed.)Molnár, Petra, Máté Ágoston Demény, Beáta Várkonyi, Zsuzsanna Polgár, Ágnes Pór, Ilona Kovács, Andrea Szegedi, Attila Gábor Szöllősi, a Magdolna Szántó. "The Clinically Applied PARP Inhibitor Talazoparib Ameliorates Imiquimod-induced Psoriasis in Mice Without Reducing Skin Inflammation." Frontiers in Pharmacology 16 (2025): 1519066. https://doi.org/10.3389/fphar.2025.1519066.
Citace podle MLA (9th ed.)Molnár, Petra, et al. "The Clinically Applied PARP Inhibitor Talazoparib Ameliorates Imiquimod-induced Psoriasis in Mice Without Reducing Skin Inflammation." Frontiers in Pharmacology, vol. 16, 2025, p. 1519066, https://doi.org/10.3389/fphar.2025.1519066.